ATR and nonpapillary renal cell carcinoma: Given the antitumor effects of monotherapy with ATRi seen in our xenograft studies, we believe that clinical studies investigating ATR inhibitor monotherapy for immune checkpoint– and TKI-resistant ccRCC cases are warranted.